More than a supply chain issue and missing the first mover status, Semaglutide episode has rather exposed systemic chinks and could prove costly for India’s pharmaceutical industry, which supplies ...

The Hikma Court correctly held that a generic manufacturer should not be liable for induced patent infringement if it carves patented uses out of its label. FDA can navigate Hikma’s aftermath without ...

Jessica Rendall is a reporter with experience covering a variety of health and wellness topics, including chronic disease, infectious disease, telemedicine, mental health and health technology. Carley ...

Two patients. Same hospital. Same diagnosis: lung cancer. Both receive the same chemotherapy. One responds well. The other doesn’t. For decades, cancer treatment followed a simple rule. Identify where ...

A generic version of a breakthrough cystic fibrosis drug, manufactured in Bangladesh for a fraction of the American price, may give some families around the world an unlikely lifeline. A generic ...

Reliable access to medicines has always mattered, but in today’s healthcare environment it has become a defining issue for pharmacy operations and patient care. Drug shortages, supply disruptions, and ...

The US Supreme Court ruled yesterday, June 4, that pharmaceutical company Hikma’s generic cardiovascular drug does not infringe global biopharmaceutical company Amarin’s patents covering its drug ...

A unanimous Supreme Court reversed the Federal Circuit and held that Amarin did not plausibly allege that Hikma’s skinny label and marketing actively induced infringement of Vascepa’s ...

WASHINGTON, June 4 (Reuters) - Drugmaker Hikma's (HIK.L), opens new tab generic version of Amarin Pharma's (AMRN.O), opens new tab cardiovascular medication Vascepa did not infringe Amarin's patents, ...

Most disputes between pharmaceutical companies and generic drugmakers end in settlements. Five years of class-action litigation over a Takeda Pharmaceutical gastrointestinal drug culminated this week ...

Hims & Hers Health (HIMS) on Thursday announced the launch of generic versions of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy semaglutide through its telehealth platform in Canada. The ...

The Trump administration has expanded TrumpRx to include more than 600 generic medications — a significant scale-up from the platform’s original focus on branded drugs under most-favored-nation ...